View Older Stories View More Recent Stories

Nov 21, 2019 06:26AM Amgen (AMGN) Completes Acquisition Of Otezla, Updates Guidance
Nov 21, 2019 06:21AM Amgen Completes Acquisition Of Otezla® (apremilast)
Nov 20, 2019 04:16PM Bristol-Myers Squibb (BMY) Completes Acquisition of Celgene (CELG)
Nov 20, 2019 04:16PM Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
Nov 20, 2019 06:59AM Bristol-Myers Squibb (BMY) Announces Update on CheckMate -915 for Opdivo Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%
Nov 20, 2019 06:58AM Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%
Nov 15, 2019 05:57PM Bristol-Myers (BMY) Receives FTC Clearance for Celgene (CELG) Acquisition, Deal Expected to Close Next Week
Nov 15, 2019 04:55PM Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
Nov 11, 2019 07:00AM Bristol-Myers Squibb (BMY) Announces FAA Accepts for Priority Review Application for Opdivo Plus Yervoy Combination for Patients with Previously Treated Advanced HCC
Nov 11, 2019 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Adva
Nov 7, 2019 06:59AM Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting¹
Oct 31, 2019 06:59AM Bristol-Myers Squibb Reports Third Quarter Financial Results
Oct 30, 2019 04:15PM Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference
Oct 30, 2019 06:59AM Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT
Oct 24, 2019 07:24AM Bristol-Myers Squibb (BMY) Announces EC Approves Opdivo 4-Week Dosing Schedule for Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease
Oct 24, 2019 06:59AM European Commission Approves Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Unde
Oct 22, 2019 07:12AM Bristol-Myers Squibb (BMY) CheckMate -9LA Meets Primary Endpoint Demonstrating Superior OS Compared to Chemotherapy Alone in First-Line Lung Cancer
Oct 22, 2019 06:59AM CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to C
Sep 30, 2019 10:30AM Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
Sep 28, 2019 10:30AM Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced No
Sep 28, 2019 02:30AM Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
Sep 28, 2019 02:30AM Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients
Sep 24, 2019 07:01AM Bristol-Myers Squibb (BMY) Reports Positive CHMP Recommendation Approval of Opdivo (nivolumab) Flat Dosing Schedule
Sep 24, 2019 06:59AM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of
Sep 20, 2019 06:59AM Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights
Sep 19, 2019 07:00AM Bristol-Myers Squibb (BMY) Says Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving OS Across Multiple Cancers
Sep 19, 2019 06:59AM Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers
Sep 12, 2019 06:59AM Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019
Sep 11, 2019 04:16PM Bristol‑Myers Squibb Announces Dividend
Sep 10, 2019 06:16AM Bristol-Myers Squibb (BMY) Announces Pooled Five-Year Survival Results for Opdivo in Previously-Treated Advanced NSCLC
Sep 10, 2019 05:30AM Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
Sep 5, 2019 07:00AM Bristol-Myers Squibb (BMY) Reports Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial
Sep 5, 2019 06:59AM Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
Sep 5, 2019 01:00AM Press Release Biocartis NV: Biocartis announces H1 2019 results
Sep 4, 2019 07:00AM BioMotiv and Bristol-Myers Squibb Form Strategic Partnership
Sep 4, 2019 07:00AM  More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research
Sep 3, 2019 06:59AM Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference
Aug 27, 2019 04:16PM European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Aug 26, 2019 06:32AM Amgen (AMGN) to Acquire Otezla from Celgene (CELG) for $13.4B
Aug 26, 2019 06:30AM Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
Aug 26, 2019 06:30AM Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Aug 5, 2019 08:00AM PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility
Aug 1, 2019 07:59AM Nektar (NKTR) and Bristol-Myers Squibb (BMY) Announce FDA Breakthrough Therapy Designation for Bempegaldesleukin with Opdivo for Treatment of Patients with Untreated Advanced Melanoma
Aug 1, 2019 07:00AM Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients
Jul 29, 2019 10:10AM Bristol-Myers Squibb (BMY) Announces European Commission Approval of Pending Acquisition of Celgene (CELG)
Jul 29, 2019 10:10AM Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
Jul 26, 2019 07:06AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval of Empliciti Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with R/R MM
Jul 26, 2019 06:59AM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory
Jul 25, 2019 06:59AM Bristol-Myers Squibb Reports Second Quarter Financial Results
Jul 24, 2019 04:49PM Bristol-Myers Squibb (BMY) Part 2 of the Phase 3 CheckMate -227 Did Not Meet Primary Endpoint
View More Recent Stories View Older Stories